Publications

Browse the Category

(Click to Jump)

Screening

Profiling of circulating glial cells for accurate blood-based diagnosis of glial malignancies

Published by: Datar Cancer Genetics
Published Year: 2023

Accurate prostate cancer detection based on enrichment and characterization of prostate cancer specific circulating tumor cells

Published by: Datar Cancer Genetics
Published Year: 2023

Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells

Published by: Datar Cancer Genetics
Published Year: 2022

Concordancy of immunocytochemistry profiling of circulating tumor cells with immunohistochemistry for analysis of therapeutically relevant biomarkers.

Published by: Datar Cancer Genetics
Published Year: 2021

PS3-13: Non-invasive screening for breast cancer risk based on circulating ensembles of tumor associated cells.

Published by: Datar Cancer Genetics
Published Year: 2021

PR01.01. Evaluation of Circulating Tumor Cells for Non-Invasively Discerning Lung Primary from Metastasis.

Published by: Datar Cancer Genetics
Published Year: 2021

Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk.

Published by: Datar Cancer Genetics
Published Year: 2021

OFP01.05 Circulating Ensembles of Tumor Associated Cells Facilitate Efficient Triaging of Asymptomatic Individuals for Low Dose Computed Tomography.

Published by: Datar Cancer Genetics
Published Year: 2021

Circulating microtumors: A functional hallmark for cancer detection and management.

Published by: Datar Cancer Genetics
Published Year: 2020

Circulating ensembles of tumor-associated cells in genitourinary cancers.

Published by: Datar Cancer Genetics
Published Year: 2020

P4-01-05: Circulating ensembles of tumor associated cells for detection of breast cancer.

Published by: Datar Cancer Genetics
Published Year: 2020

A14 Circulating Ensembles of Tumor-Associated Cells Are Ubiquitous in Lung Cancers.

Published by: Datar Cancer Genetics
Published Year: 2020

Circulating ensembles of tumor-associated cells in gastrointestinal cancers.

Published by: Datar Cancer Genetics
Published Year: 2020

Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer.

Published by: Datar Cancer Genetics
Published Year: 2019

PD01.11 Artificial Intelligence Can Detect Lung Cancer From High Resolution Microscopic Images of Conditioned Peripheral Blood.

Published by: Datar Cancer Genetics
Published Year: 2019

Circulating Ensembles of Tumor Associated Cells are Ubiquitous in Breast, Ovarian and Cervical Cancers and Atypical in Asymptomatic Individuals.

Published by: Datar Cancer Genetics
Published Year: 2019

P087 - Diagnostic non-invasive biopsy can substitute conventional tissue dependent procedures in suspected cases of renal cell carcinoma

Published by: Datar Cancer Genetics
Published Year: 2019

Liquid Biopsy for Detection of Pancreaticobiliary Cancers by Functional Enrichment and Immunofluorescent Profiling of Circulating Tumor Cells and Their Clusters

Published by: Datar Cancer Genetics
Published Year: 2024

Profiling of circulating glial cells for accurate blood-based diagnosis of glial malignancies

Published by: Datar Cancer Genetics
Published Year: 2023

Accurate prostate cancer detection based on enrichment and characterization of prostate cancer specific circulating tumor cells

Published by: Datar Cancer Genetics
Published Year: 2023

Path-24. Accurate Identification of Glial Malignancies from Peripheral Blood

Published by: Datar Cancer Genetics
Published Year: 2022

Concordancy of immunocytochemistry profiling of circulating tumor cells with immunohistochemistry for analysis of therapeutically relevant biomarkers.

Published by: Datar Cancer Genetics
Published Year: 2021

Analytical and clinical validation of the TruCheck^™ platform for diagnostic triaging of symptomatic cases suspected of colorectal cancer.

Published by: Datar Cancer Genetics
Published Year: 2020

PS2-40: Analytical and clinical validation of the trucheck™ platform for diagnostic triaging of symptomatic cases suspected of breast cancer.

Published by: Datar Cancer Genetics
Published Year: 2021

P059 Analytical and clinical validation of the trucheckTM platform for diagnostic triaging of symptomatic cases suspected of prostate cancer

Published by: Datar Cancer Genetics
Published Year: 2020

PR01.01. Evaluation of Circulating Tumor Cells for Non-Invasively Discerning Lung Primary from Metastasis.

Published by: Datar Cancer Genetics
Published Year: 2021

OFP01.05 Circulating Ensembles of Tumor Associated Cells Facilitate Efficient Triaging of Asymptomatic Individuals for Low Dose Computed Tomography.

Published by: Datar Cancer Genetics
Published Year: 2021

VP01-10 Mutational landscape and Tumor Mutation Burden of Indian NSCLC patients.

Published by: Datar Cancer Genetics
Published Year: 2020

VP01-23 Non-invasive Diagnostic Triaging of Suspected Lung Cancers based on Immunocytochemistry Profiling of Circulating Tumor Cells.

Published by: Datar Cancer Genetics
Published Year: 2020

Circulating microtumors: A functional hallmark for cancer detection and management.

Published by: Datar Cancer Genetics
Published Year: 2020

Circulating ensembles of tumor-associated cells in genitourinary cancers.

Published by: Datar Cancer Genetics
Published Year: 2020

Circulating ensembles of tumor-associated cells in gastrointestinal cancers.

Published by: Datar Cancer Genetics
Published Year: 2020

Encyclopedic liquid biopsies for guideline-compliant diagnostic work-up in gastrointestinal cancers.

Published by: Datar Cancer Genetics
Published Year: 2020

B17: An mRNA signature that accurately discerns gliomas from healthy individuals.

Published by: Datar Cancer Genetics
Published Year: 2020

B15: Circulating tumor cells express tissue specific antigens in multiple cancers.

Published by: Datar Cancer Genetics
Published Year: 2020

B62: Wholesome non-invasive liquid biopsies for pharmacodiagnostic work-up in breast cancer.

Published by: Datar Cancer Genetics
Published Year: 2020

B61: Encyclopedic noninvasive liquid biopsies for differential diagnosis in prostate cancer.

Published by: Datar Cancer Genetics
Published Year: 2020

B16: Noninvasive liquid biopsies for guideline-compliant diagnostic assessment in ovarian cancers.

Published by: Datar Cancer Genetics
Published Year: 2020

A14 Circulating Ensembles of Tumor-Associated Cells Are Ubiquitous in Lung Cancers.

Published by: Datar Cancer Genetics
Published Year: 2020

P4-01-05: Circulating ensembles of tumor associated cells for detection of breast cancer.

Published by: Datar Cancer Genetics
Published Year: 2020

BIOM-35. MULTI ANALYTE ASSAY FOR NON-INVASIVE DIAGNOSIS OF BRAIN TUMORS.

Published by: Datar Cancer Genetics
Published Year: 2020

PATH-64. PROSPECTIVE, BLINDED PLASMA BASED ANALYSIS FOR DIAGNOSIS OF NEWLY DIAGNOSED GLIOMA

Published by: Datar Cancer Genetics
Published Year: 2019

PATH-43. DIAGNOSIS OF GLIOMAS USING CIRCULATING GLIAL CELLS

Published by: Datar Cancer Genetics
Published Year: 2019

PATH-37. LIQUID BIOPSY FOR IDENTIFICATION OF NEWLY DIAGNOSED GLIOMA.

Published by: Datar Cancer Genetics
Published Year: 2018

P4-01-05: Circulating ensembles of tumor associated cells for detection of breast cancer.

Published by: Datar Cancer Genetics
Published Year: 2020

P087 - Diagnostic non-invasive biopsy can substitute conventional tissue dependent procedures in suspected cases of renal cell carcinoma

Published by: Datar Cancer Genetics
Published Year: 2019

Circulating Ensembles of Tumor Associated Cells are Ubiquitous in Breast, Ovarian and Cervical Cancers and Atypical in Asymptomatic Individuals.

Published by: Datar Cancer Genetics
Published Year: 2019

PD01.11 Artificial Intelligence Can Detect Lung Cancer From High Resolution Microscopic Images of Conditioned Peripheral Blood.

Published by: Datar Cancer Genetics
Published Year: 2019

Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging.

Published by: Datar Cancer Genetics
Published Year: 2020

Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer.

Published by: Datar Cancer Genetics
Published Year: 2019

In vitro cell killing proficiency of autologous immune cells educated with allogenic multi-cancer tumor cell lysate.

Published by: Datar Cancer Genetics
Published Year: 2024

Exploring the significance of MET overexpression by gene expression profiling versus immunohistochemistry in an EGFR-mutant lung cancer cohort.

Published by: Datar Cancer Genetics
Published Year: 2024

Spectrum of HER2 alterations in NSCLC: Comparative analysis of tissue and liquid biopsies in lung cancer.

Published by: Datar Cancer Genetics
Published Year: 2024

Molecular profiling in ABC: Is complementary testing with tissue and plasma necessary and clinically relevant?

Published by: Datar Cancer Genetics
Published Year: 2024

Real world experience of molecular landscape of uveal melanomas: Implications for personalized medicine strategies.

Published by: Datar Cancer Genetics
Published Year: 2024

Pre- and post-radical surgery comparative quantification of circulating tumor cells and circulating tumor-associated cells.

Published by: Datar Cancer Genetics
Published Year: 2024

Multidimensional tumor profiling and its meaningful impact on personalized therapy outcomes: Insights from a real-world study.

Published by: Datar Cancer Genetics
Published Year: 2024

Outcomes of personalized therapy guided by Exacta encyclopedic tumor analysis for women with broadly refractory advanced breast cancer.

Published by: Datar Cancer Genetics
Published Year: 2024

Enhancing cancer detection through AI-driven high content analysis of circulating tumor cells.

Published by: Datar Cancer Genetics
Published Year: 2024

Evaluation of Survival Outcomes in Solid Organ Cancer Patients with Brain Metastasis Treated with Exacta Encylopedic Tumor Analysis Based Treatments.

Published by: Datar Cancer Genetics
Published Year: 2024

Evaluating the clinical utility of circulating tumor cells (CTC) profiling to predict selection of preferred therapeutic regimens in newly diagnosed or pretreated refractory renal cell carcinomas (RCC).

Published by: Datar Cancer Genetics
Published Year: 2023

No checkmate in metastatic setting: Navigating real world patients applying personalized therapy based on extensive tumor profiling.

Published by: Datar Cancer Genetics
Published Year: 2023

Pan-cancer analysis of tumor mutation burden and other key ICI biomarkers in the Indian cohort.

Published by: Datar Cancer Genetics
Published Year: 2023

Liquid and tissue profiling of somatic mutational landscape of non-small cell lung cancer from an Indian cohort.

Published by: Datar Cancer Genetics
Published Year: 2023

Comprehensive molecular profiling from liquid and tissue for analysing the somatic mutational landscape in an Indian breast cancer cohort.

Published by: Datar Cancer Genetics
Published Year: 2023

Liquid and tissue profiling of targetable co-mutations with KRAS in non-small cell lung cancer.

Published by: Datar Cancer Genetics
Published Year: 2023

Banner_Journal-of-Nursing-and-Healthcare

Personalized Therapy based on Several Parameters of Comprehensive Tumour Profiling: a Challenge in NEBC

Published by: Datar Cancer Genetics
Published Year: 2022

Banner_Publication_Frontiers-in-Medicine

Case Report: Extensive Tumor Profiling in Primary Neuroendocrine Breast Cancer Cases as a Role Model for Personalized Treatment in Rare and Aggressive Cancer Types

Published by: Datar Cancer Genetics
Published Year: 2022

Multi-analyte liquid biopsies for molecular pathway guided personalized treatment selection in advanced refractory cancers: A clinical utility pilot study

Published by: Datar Cancer Genetics
Published Year: 2022

Mutational landscape and Tumor Mutation Burden of Indian NSCLC patients.

Published by: Datar Cancer Genetics
Published Year: 2020

Circulating tumor cell assay to non-invasively evaluate PD-L1 and other therapeutic targets in multiple cancers

Published by: Datar Cancer Genetics
Published Year: 2022

PS4-36: Non-invasive evaluation of chemoresistance in breast cancers using circulating tumor associated cells.

Published by: Datar Cancer Genetics
Published Year: 2021

73P Anti-angiokinases in patient-specific combination regimens can improve outcomes in advanced metastatic cancers.

Published by: Datar Cancer Genetics
Published Year: 2020

Liquid biopsies to enable non-invasive real-time functional chemoresistance profiling in solid organ cancers.

Published by: Datar Cancer Genetics
Published Year: 2020

Multi-analyte liquid biopsies based treatment in advanced refractory cancers.

Published by: Datar Cancer Genetics
Published Year: 2020

CLO20-028 Clinical Utility of Encyclopedic Tumor Analysis to Treat Breast Cancer Patients who have Failed Standard of Care Treatments.

Published by: Datar Cancer Genetics
Published Year: 2020

Encyclopedic tumor analysis guided personalized treatments for advanced refractory breast cancer.

Published by: Datar Cancer Genetics
Published Year: 2020

303 Poster - Real-time non-invasive chemoresistance profiling of circulating tumor associated cells in breast cancers to determine resistance towards mitotic inhibitors.

Published by: Datar Cancer Genetics
Published Year: 2020

302 Poster - Circulating tumor associated cells in breast cancers are resistance educated towards prior anthracycline treatments.

Published by: Datar Cancer Genetics
Published Year: 2020

Viable Circulating Ensembles of Tumor Associated Cells Persist in Patients with No Radiologically Detectable Disease after Treatment in Head and Neck Cancer.

Published by: Datar Cancer Genetics
Published Year: 2020

Circulating Tumor Associated Cells in Head, Neck Cancers are Resistance Educated per Previous Chemotherapy Treatments.

Published by: Datar Cancer Genetics
Published Year: 2020

47P Improved treatment outcomes by using patient-specific drug combinations in mTOR activated advanced metastatic cancers.

Published by: Datar Cancer Genetics
Published Year: 2020

PD-L1 profiling of circulating tumor cells for immune checkpoint inhibitor therapy in head, neck cancers.

Published by: Datar Cancer Genetics
Published Year: 2020

PD-L1 profiling of circulating tumor cells for immune checkpoint inhibitor therapy in gastroesophageal cancers.

Published by: Datar Cancer Genetics
Published Year: 2020

Effect of previous chemotherapy treatments on circulating tumor-associated cells in colorectal cancer.

Published by: Datar Cancer Genetics
Published Year: 2020

A49: Viable circulating ensembles of tumor-associated cells persist in pretreated patients with solid organ cancers showing no radiologically detectable disease.

Published by: Datar Cancer Genetics
Published Year: 2020

B35 Circulating Tumor-Associated Cells in Lung Cancers Are Resistance-Educated per Previous Chemotherapy Treatments.

Published by: Datar Cancer Genetics
Published Year: 2020

11P - PD-L1 profiling of circulating tumour cells is a viable companion diagnostic for checkpoint inhibitor therapy in lung cancer.

Published by: Datar Cancer Genetics
Published Year: 2019

P4-01-17: Viable circulating ensembles of tumor associated cells persist in patients with no radiologically detectable disease after treatment in breast cancer.

Published by: Datar Cancer Genetics
Published Year: 2020

P6-10-11: In vitro chemo interrogation of viable circulating tumor associated cells from breast cancer patients.

Published by: Datar Cancer Genetics
Published Year: 2020

371P - Clinical utility of Encyclopedic tumour analysis to treat patients advanced refractory head, neck cancers

Published by: Datar Cancer Genetics
Published Year: 2019

INNV-26. IN VITRO CHEMO RESISTANCE PROFILES OF CIRCULATING GLIAL CELLS REPLICATE CHEMO CHARACTERISTICS OF TUMOR TISSUE

Published by: Datar Cancer Genetics
Published Year: 2019

CMET-37. CLINICAL UTILITY OF ENCYCLOPEDIC TUMOR ANALYSIS TO TREAT PATIENTS WITH BRAIN METASTASIS IN REFRACTORY CANCERS

Published by: Datar Cancer Genetics
Published Year: 2019

102P - Encyclopedic tumour analysis (ETA) guided combination regimens of hormone receptor antagonists with other systemic agents for treatment of refractory cancers.

Published by: Datar Cancer Genetics
Published Year: 2019

45P - Circulating tumour associated cells in esophageal cancers are resistance educated per previous chemo treatments.

Published by: Datar Cancer Genetics
Published Year: 2019

Encyclopedic Tumor Analysis Guided Treatments with Conventional Drugs Outperform Available Alternatives in Refractory Head, Neck Cancers.

Published by: Datar Cancer Genetics
Published Year: 2020

94P - Encyclopedic tumour analysis guided treatments with conventional drugs outperform available alternatives in refractory cancers.

Published by: Datar Cancer Genetics
Published Year: 2019

Tumor infiltrating lymphocytes show in vitro cytotoxic activity against tumor cells in multiple cancers.

Published by: Datar Cancer Genetics
Published Year: 2019

Clinical efficacy of combination therapies with androgen receptor antagonists for treatment of multiple refractory cancers.

Published by: Datar Cancer Genetics
Published Year: 2019

PD01.10 Diagnostic Non-Invasive Biopsy Can Substitute Conventional Tissue Dependent Procedures in Suspected Cases of Lung Cancer.

Published by: Datar Cancer Genetics
Published Year: 2019

1934P - Encyclopedic tumor analysis for organ agnostic treatment with Axitinib in combination regimens for advanced cancers.

Published by: Datar Cancer Genetics
Published Year: 2019

1972P - In vitro functional interrogation of viable circulating tumor associated cells (C-TACs) for evaluating platin resistance

Published by: Datar Cancer Genetics
Published Year: 2019

Response to pazopanib-based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma

Published by: Datar Cancer Genetics
Published Year: 2021

Excellent Response with Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma with PIK3CA Mutation and High Androgen Receptor Expression-A Case Report.

Published by: Datar Cancer Genetics
Published Year: 2021

A case report of androgen receptor inhibitor therapy in recurrent high-grade serous ovarian cancer.

Published by: Datar Cancer Genetics
Published Year: 2020

Liquid biopsy and multi-analyte testing guided treatment of HER2 positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapy.

Published by: Datar Cancer Genetics
Published Year: 2020

111P - mTOR inhibitors in combination regimens guided by encyclopedic tumour analysis show superior outcomes compared to monotherapy in refractory cancers.

Published by: Datar Cancer Genetics
Published Year: 2019

Long Overall Survival in a Case of Refractory Stage IV Squamous Cell Carcinoma of Lung Treated with Personalized De Novo Combination Regimen.

Published by: Datar Cancer Genetics
Published Year: 2020

Adaptive, Iterative, Long-Term Personalized Therapy Management in a Case of Stage IV Refractory NSCLC

Published by: Datar Cancer Genetics
Published Year: 2019

Liquid biopsy in periampullary carcinoma.

Published by: Datar Cancer Genetics
Published Year: 2016

Angiogenesis Inhibitors in Personalized Combination Regimens for the Treatment of Advanced Refractory Cancers.

Published by: Datar Cancer Genetics
Published Year: 2021

Improved Treatment Outcomes by Using Patient Specific Drug Combinations in Mammalian Target of Rapamycin Activated Advanced Metastatic Cancers.

Published by: Datar Cancer Genetics
Published Year: 2021

Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumors.

Published by: Datar Cancer Genetics
Published Year: 2021

Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors.

Published by: Datar Cancer Genetics
Published Year: 2020

Re-establishing Responsiveness in a Case of Refractory Metastatic Rectal Cancer with a Personalized de novo Combination Regimen.

Published by: Datar Cancer Genetics
Published Year: 2021

Multi-analyte interrogation-based treatment of advanced refractory cancers.

Published by: Datar Cancer Genetics
Published Year: 2020

Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers: results from the RESILIENT trial.

Published by: Datar Cancer Genetics
Published Year: 2019

PS4-36: Non-invasive evaluation of chemoresistance in breast cancers using circulating tumor associated cells.

Published by: Datar Cancer Genetics
Published Year: 2021

Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumors.

Published by: Datar Cancer Genetics
Published Year: 2021

303 Poster - Real-time non-invasive chemoresistance profiling of circulating tumor associated cells in breast cancers to determine resistance towards mitotic inhibitors.

Published by: Datar Cancer Genetics
Published Year: 2020

Circulating microtumors: A functional hallmark for cancer detection and management.

Published by: Datar Cancer Genetics
Published Year: 2020

P6-10-11: In vitro chemo interrogation of viable circulating tumor associated cells from breast cancer patients.

Published by: Datar Cancer Genetics
Published Year: 2020

P4-01-17: Viable circulating ensembles of tumor associated cells persist in patients with no radiologically detectable disease after treatment in breast cancer.

Published by: Datar Cancer Genetics
Published Year: 2020

B35 Circulating Tumor-Associated Cells in Lung Cancers Are Resistance-Educated per Previous Chemotherapy Treatments.

Published by: Datar Cancer Genetics
Published Year: 2020

A49: Viable circulating ensembles of tumor-associated cells persist in pretreated patients with solid organ cancers showing no radiologically detectable disease.

Published by: Datar Cancer Genetics
Published Year: 2020

PD-L1 profiling of circulating tumor cells for immune checkpoint inhibitor therapy in gastroesophageal cancers.

Published by: Datar Cancer Genetics
Published Year: 2020

PD-L1 profiling of circulating tumor cells for immune checkpoint inhibitor therapy in head, neck cancers.

Published by: Datar Cancer Genetics
Published Year: 2020

Circulating Tumor Associated Cells in Head, Neck Cancers are Resistance Educated per Previous Chemotherapy Treatments.

Published by: Datar Cancer Genetics
Published Year: 2020

Viable Circulating Ensembles of Tumor Associated Cells Persist in Patients with No Radiologically Detectable Disease after Treatment in Head and Neck Cancer.

Published by: Datar Cancer Genetics
Published Year: 2020

302 Poster - Circulating tumor associated cells in breast cancers are resistance educated towards prior anthracycline treatments.

Published by: Datar Cancer Genetics
Published Year: 2020

Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors.

Published by: Datar Cancer Genetics
Published Year: 2020

Adaptive, Iterative, Long-Term Personalized Therapy Management in a Case of Stage IV Refractory NSCLC

Published by: Datar Cancer Genetics
Published Year: 2019

1972P - In vitro functional interrogation of viable circulating tumor associated cells (C-TACs) for evaluating platin resistance

Published by: Datar Cancer Genetics
Published Year: 2019

11P - PD-L1 profiling of circulating tumour cells is a viable companion diagnostic for checkpoint inhibitor therapy in lung cancer.

Published by: Datar Cancer Genetics
Published Year: 2019

PD01.10 Diagnostic Non-Invasive Biopsy Can Substitute Conventional Tissue Dependent Procedures in Suspected Cases of Lung Cancer.

Published by: Datar Cancer Genetics
Published Year: 2019

45P - Circulating tumour associated cells in esophageal cancers are resistance educated per previous chemo treatments.

Published by: Datar Cancer Genetics
Published Year: 2019

Datar Cancer Genetics

Datar Cancer Genetics

Datar Cancer Genetics

Publications

Browse the Category

(Click to Jump)

(Click to Jump)

(Click to Jump)

(Click to Jump)

Screening

Diagnosis

Therapy Guidance

Monitoring

Request a Call Back